Business Context and Reporting Period
This Form 8-K was filed by Processa Pharmaceuticals, Inc. on May 25, 2021, reporting an event that occurred on May 21, 2021. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol PCSA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance data.
Material Changes
On May 21, 2021, Processa Pharmaceuticals, Inc. notified Akashi Therapeutics, Inc. in writing of its decision to terminate the Licensing Agreement dated August 29, 2019. Pursuant to the terms of the Termination Notice, the effective date of termination is set for August 25, 2021.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the termination of the material definitive agreement. No unusual items or contingencies were disclosed in this text.
Investor Verification Checklist
- Verify the specific terms of the terminated Licensing Agreement with Akashi Therapeutics, Inc. dated August 29, 2019.
- Confirm the effective termination date of August 25, 2021, and any associated financial obligations or penalties.
- Assess the impact of this termination on Processa's product pipeline and future revenue streams.
- Review subsequent filings for any updates regarding the status of the agreement or new licensing arrangements.